Table 1.
Target | Cell Line(s) | Cranberry Constituent | In Vitro Results [Reference(s)] |
---|---|---|---|
Breast | MCF-7 | CE | ↑ apoptosis [23]; ↑ G1 cell cycle arrest [23] |
↓ cell viability [23,24] | |||
CJE | ↓ cell viability [25] | ||
C-PAC | ↓ cell density [26] | ||
FG | ↓ cell viability [27] | ||
Fr6 | ↓ cell viability [28] | ||
Q | ↓ cell viability [27] | ||
UA | ↓ cell density [29,30]; ↓ cell viability [27] | ||
MDA-MB-435* | CJE | ↓ cell viability [25] | |
Fr6 | ↑ apoptosis [28]; ↑ G2-M cell cycle arrest [28] | ||
↓ cell viability [28] | |||
UA | ↓ cell density [29] | ||
Cervix | ME180 | C-PAC | ↓ cell density [26] |
UA | ↓ cell density [30] | ||
Colon | Caco-2 | CJE | ↓ cell viability [25] |
TP | ↓ lipid peroxidation [31] | ||
↓ pro-inflammatory markers TNFα and IL-6 [31] | |||
HT-29 | ANTHO | ↓ cell viability [32] | |
CE | ↓ cell viability [24,33] | ||
↓ pro-inflammatory marker COX-2 [34] | |||
C-PAC | ↑ apoptosis [35]; ↓ cell density [26] | ||
↓ cell viability [36] | |||
CJE | ↓ cell viability [32] | ||
Fr6 | ↓ cell viability [36] | ||
TP | ↓ cell viability [32] | ||
UA | ↑ apoptosis [35]; ↓ cell density [29,30] | ||
↓ cell viability [35] | |||
HCT116 | CE | ↓ cell viability [33] | |
C-PAC | ↑ apoptosis [35]; ↓ cell viability [35] | ||
UA | ↑ apoptosis [35]; ↓ cell density [29] | ||
↓ cell viability [35] | |||
LS-513 | ANTHO | ↓ cell viability [32] | |
CJE | ↓ cell viability [32] | ||
TP | ↓ cell viability [32] | ||
SW460 | TP | ↓ cell viability [33] | |
SW620 | TP | ↓ cell viability [24] | |
C-PAC | ↓ cell proliferation [37] | ||
Esophagus | CP-C | C-PAC | ↓ total reactive oxygen species [38] |
JHEsoAD1 | C-PAC | ↑ autophagy in acid-sensitive cells, pro-death [39,40] | |
↑ necrosis in acid-resistant cells [39] | |||
↑ G2-M cell cycle arrest [39] | |||
↑ total reactive oxygen species [38] | |||
↑ hydrogen peroxide levels [38] | |||
↓ cell viability [40,41] | |||
↓ PI3K/AKT/mTOR signaling [39] | |||
OE33 | C-PAC | ↑ autophagy in acid-sensitive cells [39] | |
↑ low levels of apoptosis [39]↑ G2-M cell cycle arrest [39] | |||
↓ cell proliferation [39] | |||
↑ total reactive oxygen species [38] | |||
↓ PI3K/AKT/mTOR signaling [39] | |||
OE19 | C-PAC | ↑ necrosis in acid-resistant cells [39] | |
↑ G2-M cell cycle arrest with significant S-phase delay [39] | |||
↑ total reactive oxygen species [38] | |||
↑ hydrogen peroxide levels [38] | |||
↓ PI3K/AKT/mTOR signaling [39] | |||
↓ cell viability [40,41] | |||
Glioblastoma | SF295 | UA | ↓ cell density [29] |
U87 | C-PAC | ↑ apoptosis [36]; ↑ G1 cell cycle arrest [36] | |
↓ cell viability [36] | |||
Fr6 | ↑ apoptosis [36]; ↑ G1 cell cycle arrest [36] | ||
↓ cell viability [28] | |||
Leukemia | K562 | C-PAC | ↓ cell density [26] |
RPMI8226 | UA | ↓ cell density [29] | |
Liver | HepG2 | CE | ↑ reduced glutathione levels [22] |
↓ glutathione peroxidase activity [22] | |||
↓ lipid peroxidation [22] | |||
↓ reactive oxygen species [22] | |||
CJE | ↑ reduced glutathione levels [22] | ||
↓ glutathione peroxidase activity [22] | |||
↓ lipid peroxidation [22] | |||
↓ reactive oxygen species [22] | |||
FG | ↓ cell viability [27] | ||
Q | ↓ cell viability [27] | ||
UA | ↓ cell viability [27] | ||
Lung | DMS114 | Fr6 | ↓ cell viability [28] |
NCI-H322M | UA | ↓ cell density [29] | |
NCI-H460 | C-PAC | ↑ apoptosis [37,42]; ↑ G1 cell cycle arrest [37] | |
↓ cell density [26]; ↓ cell viability [37] | |||
↓ cell proliferation [37] | |||
UA | ↓ cell density [29,30] | ||
Lymphoma | Rev-2-T-6 | NDM | ↓ cell viability [43] |
↓ extracellular matrix invasion [43] | |||
Melanoma | M14 | C-PAC | ↓ cell density [26] |
UA | ↓ cell density [30] | ||
SK-MEL5 | Fr6 | ↓ cell viability [28] | |
Neuroblastoma | IMR-32 | C-PAC | ↓ cell viability [44] |
SH-Sy5Y | C-PAC | ↓ cell viability [44] | |
SK-N-SH | C-PAC | ↓ cell viability [44] | |
SMS-KCNR | C-PAC | ↑ apoptosis [44]; ↑ G2-M cell cycle arrest [44] | |
↑ reactive oxygen species [44] | |||
↓ PI3K/AKT/mTOR signaling [44] | |||
↓ cell viability [44,45] | |||
Oral Cavity | CAL27 | CE | ↑ apoptosis [46]; ↓ cell adhesion [46] |
↓ cell density [46]; ↓ cell viability [24] | |||
TP | ↓ cell viability [33] | ||
HSC2 | CJE | ↑ reduced glutathione levels [47] | |
↓ cell viability [47] | |||
KB | CE | ↓ cell viability [24] | |
TP | ↓ cell viability [33] | ||
SCC25 | CE | ↑ apoptosis [46]; ↓ cell adhesion [46] | |
↓ cell density [46] | |||
Ovary | OVCAR-8 | C-PAC | ↑ G2-M cell cycle arrest [48]; ↓ cell viability [48] |
SKOV-3 | C-PAC | ↑ apoptosis [48,49]; ↑ G2-M cell cycle arrest [48,49] | |
↑ reactive oxygen species [49] | |||
↓ AKT signaling [49] | |||
↓ cell proliferation [45,49] | |||
↓ cell viability [45,48,49] | |||
Prostate | 22Rv1 | CE | ↓ cell viability [33] |
TP | ↓ cell viability [33] | ||
DU-145 | CE | ↑ G1 cell cycle arrest [50] | |
↓ cell viability [50,51] | |||
C-PAC | ↑ apoptosis [51] | ||
↑ MAPK signaling [52] | |||
↓ cell viability [26,36,51,52] | |||
↓ matrix metalloprotease activity [52] | |||
↓ PI3K/AKT signaling [52] | |||
Fr6 | ↓ cell viability [28,36] | ||
LNCaP | CE | ↓ cell viability [24] | |
PC3 | CJE | ↑ G1 cell cycle arrest [25] | |
↓ cell viability [25] | |||
C-PAC | ↓ cell density [26] | ||
UA | ↓ cell density [30] | ||
RWPE-1 | CE | ↓ cell viability [33] | |
C-PAC | ↓ cell viability [33] | ||
TP | ↓ cell viability [33] | ||
RWPE-2 | CE | ↓ cell viability [33] | |
C-PAC | ↓ cell viability [33] | ||
TP | ↓ cell viability [33] | ||
Renal | RXF393 | UA | ↓ cell density [29] |
SN12C | UA | ↓ cell density [29] | |
TK-10 | UA | ↓ cell density [29] | |
Stomach | AGS | CJE | ↓ cell viability [25] |
SGC-7901 | CE | ↑ apoptosis [53] | |
↓ cell proliferation [53] | |||
↓ cell viability [53] |
Cranberry derived constituents are abbreviated as follows: anthocyanins (ANTHO), organic-soluble cranberry extract (CE), cranberry juice extract (CJE), cranberry proanthocyanidin-rich fraction (C-PAC), flavonoid-rich fraction 6 (Fr6), flavonoid glycosides (FG), non-dialyzable material from cranberry juice concentrate (NDM), total polyphenolic fraction (TP), quercetin (Q) or ursolic acid fraction (UA). Additional abbreviations: Phosphoinositide 3-kinase (PI3K), Protein Kinase B (AKT), mechanistic Target of Rapamycin (mTOR), mitogen-activated protein kinase (MAPK). Note: MDA-MB-435* was misidentified as a breast cancer cell line, but is now confirmed to be of melanoma origin.